Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
Sign Up to like & getrecommendations! Published in 2020 at "Antibodies"
DOI: 10.3390/antib9020017
Abstract: Therapeutic monoclonal antibodies for the treatment of cancer came of age in 1997, with the approval of anti-CD20 Rituximab. Since then, a wide variety of antibodies have been developed with many different formats and mechanisms… read more here.
Keywords: antibodies combined; cancer strategies; strategies based; combined anti ... See more keywords